Abstract 2892
Background
Preclinical data suggest synergistic antitumor activity when a PARP inhibitor (PARPi) is combined with an androgen pathway inhibitor. The addition of a PARPi to abiraterone acetate and prednisone (AAP) shows improved radiographic progression-free survival (rPFS) versus AAP alone in patients with mCRPC regardless of the presence of DNA repair gene defects (DRD).1 Interim results from a phase 1 study2 support safety and tolerability of a combination of niraparib 200 mg plus AAP in patients with mCRPC. The objective of this Phase 3 study is to compare the efficacy and safety of niraparib plus AAP versus AAP with placebo as first-line therapy for mCRPC.
Trial design
The multicenter global MAGNITUDE study will open in 300 sites and 28 countries and will enroll patients with mCRPC untreated with other than ongoing androgen deprivation therapy [ADT] and ≤4 months of exposure to AAP. Cohort 1 (n = 400) will comprise patients whose tumors have DRD, as determined by either a blood or tissue assay. Cohort 2 (n = 600) will enroll patients whose tumors are not DRD +ve. Enrollment began in February 2019. The primary objective of the study is to compare radiographic progression-free survival (rPFS) for patients treated with niraparib and AAP versus AAP and placebo as first-line therapy for mCRPC. To test superiority of combination vs AAP, sample sizes were estimated to provide ≥92% power to detect HR ≤ 0.67 in the two cohorts at a 2-tailed level of significance of 0.05. Major secondary objectives are to assess the effect of the combination treatment on overall survival, time to chronic opioid use, time to pain progression and time to cytotoxic chemotherapy. Safety and pharmacokinetic profiles will be evaluated.
Clinical trial identification
NCT03748641.
Editorial acknowledgement
Ann C Sherwood, PhD with funding from Janssen Pharmaceuticals.
Legal entity responsible for the study
Janssen Pharmaceuticals.
Funding
Janssen Pharmaceuticals.
Disclosure
K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: ESSA; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Tokai; Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Meyers Squibb; Research grant / Funding (institution): Merck. D. Rathkopf: Research grant / Funding (institution): Tracon Pharma; Research grant / Funding (institution): Genentech Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Taiho Pharmaceuticals; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Ferring; Research grant / Funding (institution): Millennium; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Janssen Oncology. G. Attard: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Veridex; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche Ventana; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Millennium; Advisory / Consultancy, Travel / Accommodation / Expenses: Abbott; Advisory / Consultancy, Travel / Accommodation / Expenses: Essa; Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony: Takeda; Speaker Bureau / Expert testimony: Sanofi Aventis. M.R. Smith: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Gilead; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer. E. Efstathiou: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Oric Pharma; Advisory / Consultancy: Bayer; Advisory / Consultancy: Tolmar; Research grant / Funding (self): Astellas; Research grant / Funding (self): Pfizer. D. Olmos: Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution): Janssen Oncology; Advisory / Consultancy: Clovis; Travel / Accommodation / Expenses: Ipsen; Research grant / Funding (self), Research grant / Funding (institution): Genentech. E.J. Small: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Fortis Therpeutics; Shareholder / Stockholder / Stock options: Harpoon Therapeutics; Honoraria (self), Advisory / Consultancy: Janssen; Advisory / Consultancy: Beigene. P. Sieber: Speaker Bureau / Expert testimony, Research grant / Funding (self): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony, Research grant / Funding (self): Dendreon; Research grant / Funding (self): Janssen; Research grant / Funding (self): Allergan; Research grant / Funding (self): Effector; Research grant / Funding (self): Myovant; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): Hinova; Research grant / Funding (self): Merck. C. Dunshee: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ferring; Advisory / Consultancy: Sanofi Genzyme; Research grant / Funding (institution): Astellas Medivation; Research grant / Funding (institution): Janssen Oncology; Research grant / Funding (institution): Dendreon; Research grant / Funding (institution): Eleven Biotherapeutics; Research grant / Funding (institution): Myovant Sciences; Research grant / Funding (institution): Siemens; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Exact Sciences; Research grant / Funding (institution): TesoRx Pharmaceuticals. D. Ricci: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. J.S. Simon: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. X. Zhao: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. N. Kothari: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. S. Cheng: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. S.K. Sandhu: Honoraria (self), Research grant / Funding (institution): Merck Serono; Honoraria (self): Merck Sharp & Dohme; Honoraria (self): Roche/Genentech; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Travel / Accommodation / Expenses: Janssen; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Tolmar. All other authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract